Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Brief Summary: Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that specific disease.